Weaponizing natural killer cells for solid cancer immunotherapy

被引：22

作者：

Wong, Joshua K. M. ^{[1
]}

Dolcetti, Riccardo ^{[1
,2
,3
,4
]}

Rhee, Handoo ^{[5
,6
,7
]}

Simpson, Fiona ^{[1
]}

Souza-Fonseca-Guimaraes, Fernando ^{[1
]}

机构：

[1] Univ Queensland, Diamantina Inst, Woolloongabba, Qld 4102, Australia

[2] Peter MacCallum Canc Ctr, Melbourne, Vic 3000, Australia

[3] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Melbourne, Vic 3010, Australia

[4] Univ Melbourne, Dept Microbiol & Immunol, Melbourne, Vic 3010, Australia

[5] Princess Alexandra Hosp, Woolloongabba, Qld 4102, Australia

[6] Queen Elizabeth Jubilee II Hosp, Woolloongabba, Qld 4102, Australia

[7] Univ Queensland, Sch Med, Woolloongabba, Qld 4102, Australia

来源：

TRENDS IN CANCER | 2023年 / 9卷 / 02期

基金：

澳大利亚国家健康与医学研究理事会;

关键词：

CIK CELLS; NK CELLS; T-CELLS; ANTIBODY; CYTOTOXICITY; CD16; ENHANCEMENT;

D O I：

10.1016/j.trecan.2022.10.009

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Enhancing natural killer (NK) cell-based innate immunity has become a promis-ing strategy for immunotherapy against hard-to-cure solid cancers. Monoclonal antibody (mAb) therapy has been used to activate NK-cell-mediated antibody-dependent cellular cytotoxicity (ADCC) towards solid cancers. Cancer cells, however, can subvert immunosurveillance using multiple immunosuppressive mechanisms, which may hamper NK cell ADCC. Mechanisms to safely enhance ADCC by NK cells, such as utilizing temporary inhibition of receptor endocytosis to increase antibody presentation from target to effector cells can now be used to enhance NK-cell-mediated ADCC against solid tumors. This review summa-rizes and discusses the recent advances in the field and highlights current and potential future use of immunotherapies to maximize the therapeutic efficacy of innate anticancer immunity.

引用

页码：111 / 121

页数：11

共 80 条

[1] The CD3ζ adaptor structure determines functional differences between human and mouse CD16 Fc receptor signaling [J].

Aguilar, Oscar A. ;

Fong, Lam-Kiu ;

Ishiyama, Kenichi ;

DeGrado, William F. ;

Lanier, Lewis L. .

JOURNAL OF EXPERIMENTAL MEDICINE, 2022, 219 (05)

[2] Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells [J].

Andre, Pascale ;

Denis, Caroline ;

Soulas, Caroline ;

Bourbon-Caillet, Clarisse ;

Lopez, Julie ;

Arnoux, Thomas ;

Blery, Mathieu ;

Bonnafous, Cecile ;

Gauthier, Laurent ;

Morel, Ariane ;

Rossi, Benjamin ;

Remark, Romain ;

Breso, Violette ;

Bonnet, Elodie ;

Habif, Guillaume ;

Guia, Sophie ;

Lalanne, Ana Ines ;

Hoffmann, Caroline ;

Lantz, Olivier ;

Fayette, Jerome ;

Boyer-Chammard, Agnes ;

Zerbib, Robert ;

Dodion, Pierre ;

Ghadially, Hormas ;

Jure-Kunkel, Maria ;

Morel, Yannis ;

Herbst, Ronald ;

Narni-Mancinelli, Emilie ;

Cohen, Roger B. ;

Vivier, Eric .

CELL, 2018, 175 (07) :1731-+

[3] A natural killer-dendritic cell axis defines checkpoint therapy-responsive tumor microenvironments [J].

Barry, Kevin C. ;

Hsu, Joy ;

Broz, Miranda L. ;

Cueto, Francisco J. ;

Binnewies, Mikhail ;

Combes, Alexis J. ;

Nelson, Amanda E. ;

Loo, Kimberly ;

Kumar, Raj ;

Rosenblum, Michael D. ;

Alvarado, Michael D. ;

Wolf, Denise M. ;

Bogunovic, Dusan ;

Bhardwaj, Nina ;

Daud, Adil, I ;

Ha, Patrick K. ;

Ryan, William R. ;

Pollack, Joshua L. ;

Samad, Bushra ;

Asthana, Saurabh ;

Chan, Vincent ;

Krummel, Matthew F. .

NATURE MEDICINE, 2018, 24 (08) :1178-1191

[4] Modulation of the intracellular inhibitory checkpoint SHP-1 enhances the antitumor activity of engineered NK cells [J].

Ben-Shmuel, Aviad ;

Biber, Guy ;

Sabag, Batel ;

Barda-Saad, Mira .

CELLULAR & MOLECULAR IMMUNOLOGY, 2021, 18 (05) :1314-1316

[5] Harnessing Natural Killer Immunity in Metastatic SCLC [J].

Best, Sarah A. ;

Hess, Jonas B. ;

Souza-Fonseca-Guimaraes, Fernando ;

Cursons, Joseph ;

Kersbergen, Ariena ;

Dong, Xueyi ;

Rautela, Jai ;

Hyslop, Stephanie R. ;

Ritchie, Matthew E. ;

Davis, Melissa J. ;

Leong, Tracy L. ;

Irving, Louis ;

Steinfort, Daniel ;

Huntington, Nicholas D. ;

Sutherland, Kate D. .

JOURNAL OF THORACIC ONCOLOGY, 2020, 15 (09) :1507-1521

[6] NK Cells Stimulate Recruitment of cDC1 into the Tumor Microenvironment Promoting Cancer Immune Control [J].

Boettcher, Jan P. ;

Bonavita, Eduardo ;

Chakravarty, Probir ;

Blees, Hanna ;

Cabeza-Cabrerizo, Mar ;

Sammicheli, Stefano ;

Rogers, Neil C. ;

Sahai, Erik ;

Zelenay, Santiago ;

Reis e Sousa, Caetano .

CELL, 2018, 172 (05) :1022-+

[7] Minimal requirement for induction of natural cytotoxicity and intersection of activation signals by inhibitory receptors [J].

Bryceson, Yenan T. ;

Ljunggren, Hans-Gustaf ;

Long, Eric O. .

BLOOD, 2009, 114 (13) :2657-2666

[8] Retargeting cytokine-induced killer cell activity by CD16 engagement with clinical-grade antibodies [J].

Cappuzzello, Elisa ;

Tosi, Anna ;

Zanovello, Paola ;

Sommaggio, Roberta ;

Rosato, Antonio .

ONCOIMMUNOLOGY, 2016, 5 (08)

[9] Obinutuzumab-mediated high-affinity ligation of FcγRIIIA/CD16 primes NK cells for IFNγ production [J].

Capuano, Cristina ;

Pighi, Chiara ;

Molfetta, Rosa ;

Paolini, Rossella ;

Battella, Simone ;

Palmieri, Gabriella ;

Giannini, Giuseppe ;

Belardinilli, Francesca ;

Santoni, Angela ;

Galandrini, Ricciarda .

ONCOIMMUNOLOGY, 2017, 6 (03)

[10] Hypoxia induces an endometrial cancer stem-like cell phenotype via HIF-dependent demethylation of SOX2 mRNA [J].

Chen, Guofang ;

Liu, Binya ;

Yin, Shasha ;

Li, Shuangdi ;

Guo, Yu'e ;

Wang, Mengfei ;

Wang, Kai ;

Wan, Xiaoping .

ONCOGENESIS, 2020, 9 (09)

← 1 2 3 4 5 6 7 8 →